Thenappan Chandrasekar
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Articles (11)
Objective To compare the peri‐operative outcomes of radical prostatectomy (RP) for locally advanced, node‐positive, and metastatic prostate cancer (PCa), as determined through pathological staging, using the American College of Surgeons National Surgical Quality Improvement Project. Methods We identified RP procedures performed between 2019 and 2021. Patients were stratified by pathological staging to compare the effect of locally advanced disease (T3‐4), node positivity (N+) and metastasis (M+) vs localised PCa (T1‐2 N0 M0). Baseline demographics and 30‐day outcomes, including operating time, length of hospital stay (LOS), 30‐day mortality, readmissions, reoperations, major complications, minor complications and surgery‐specific complications, were compared between groups. Results Pathological staging data were available for 9276 RPs. Baseline demographics were comparable. There was a slightly higher rate of minor complications in the locally advanced cohort, but no significant difference in major complications, 30‐day mortality, readmissions, or rectal injuries. Node positivity was associated with longer operating time, LOS, and some slightly increased rates of 30‐day complications. RP in patients with metastatic disease appeared to be similarly safe to RP in patients with M0 disease, although it was associated with a longer LOS and slightly increased rates of certain complications. Conclusions For patients with pathologically determined locally advanced, node‐positive, and metastatic PCa, RP appears to be safe, and is not associated with significantly higher rates of 30‐day mortality or major complications compared to RP for localised PCa. This study adds to the growing body of literature investigating the role of RP for advanced PCa; further studies are needed to better characterise the risks and benefits of surgery in such patients.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Collaborators (3)
Ardalanejaz Ahmad
Assistant Professor
University of Manitoba
Alicia Morgans
Dana-Farber Cancer Institute
Hanan Goldberg
Assistant Professor
SUNY Upstate Medical University
Make your next move.
Prepare your application
Review drafts before you send them.